← Lexeo Therapeutics (LXEO)

Lexeo Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 8-KNov. 16, 2026, 7:02 a.m. ETView on SEC.gov

    Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedLexeo Therapeutics Q3 2026 net loss of $0.43 per share misses $0.32 consensus, while LX2020 interim data show 80% NSVT reduction

  • 8-KSept. 29, 2026, 4:20 p.m. ETView on SEC.gov

    Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Financial statements and exhibits

  • 8-KSept. 22, 2026, 7:08 a.m. ETView on SEC.gov

    Entry into a material definitive agreement · Other events · Financial statements and exhibits

  • 8-KAug. 12, 2026, 7:02 a.m. ETView on SEC.gov

    Results of operations and financial condition · Other events · Financial statements and exhibits